Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase...

por Li, Junlong, Sasane, Medha, Zhang, Jie, Zhao, Jing, Ricculli, Marie Louise, Yao, Zhiwen, Redhu, Suman, Signorovitch, James
Publicado 2018

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

por Cristofanilli, Massimo, Johnston, Stephen R. D., Manikhas, Alexey, Gomez, Henry L., Gladkov, Oleg, Shao, Zhimin, Safina, Sufia, Blackwell, Kimberly L., Alvarez, Ricardo H., Rubin, Stephen D., Ranganathan, Sulabha, Redhu, Suman, Trudeau, Maureen E.
Publicado 2012

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

por Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Gazzah, Anas, Lassen, Ulrik, Stein, Alexander, Wen, Patrick Y., Dietrich, Sascha, de Jonge, Maja J. A., Blay, Jean-Yves, Italiano, Antoine, Yonemori, Kan, Cho, Daniel C., de Vos, Filip Y. F. L., Moreau, Philippe, Fernandez, Elena Elez, Schellens, Jan H. M., Zielinski, Christoph C., Redhu, Suman, Boran, Aislyn, Passos, Vanessa Q., Ilankumaran, Palanichamy, Bang, Yung-Jue
Publicado 2023